GO:0050479 glyceryl-ether monooxygenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050479 describes glyceryl-ether monooxygenase activity, the enzyme activity that cleaves the ether bond of 1-alkyl-sn-glycerol in a tetrahydrobiopterin-dependent reaction.
• The reaction consumes O2 and a tetrahydropterin cofactor and produces 1-hydroxyalkyl-sn-glycerol, water and a dihydropterin.
• The activity is widespread across rat tissues and is associated with microsomal membranes.
• The enzyme resembles aromatic amino acid hydroxylases in its dependence on metal ions and tetrahydrobiopterin.
• Loss or inhibition of this activity affects ether lipid metabolism and has been linked to adipogenesis and biopterin-related metabolic disorders.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal dissection of glyceryl-ether monooxygenase activity in cells and animals.
Description
Glyceryl-ether monooxygenase activity (GO:0050479) is a molecular function that catalyzes the oxidative cleavage of the ether bond in 1-alkyl-sn-glycerol, using molecular oxygen and a tetrahydropterin cofactor. This activity is central to ether lipid metabolism, a branch of lipid biochemistry that produces plasmalogens and other ether-linked lipids with roles in membrane structure and signaling. The enzyme was historically studied as glyceryl-ether monooxygenase (EC 1.14.16.5) and is now often referred to as alkylglycerol monooxygenase (AGMO). Researchers care about GO:0050479 because it defines a specific, measurable catalytic step that can be perturbed genetically and pharmacologically. The activity has been detected in many rat tissues, indicating broad physiological relevance. Its dependence on tetrahydrobiopterin and metal ions places it in the same cofactor-dependent mechanistic family as aromatic amino acid hydroxylases, which has implications for interpreting metabolic and neurological phenotypes. Because the reaction sits at the intersection of lipid metabolism and pterin biochemistry, it is relevant to disorders of biopterin metabolism and to cellular processes such as adipogenesis. Studying GO:0050479 therefore requires both enzymatic assays and genetic models that isolate this activity from related lipid-modifying enzymes.
glyceryl-ether monooxygenase activity At A Glance
| GO ID | GO:0050479 |
|---|---|
| GO term | glyceryl-ether monooxygenase activity |
| Ontology | molecular_function |
| Synonym | alkylglycerol monooxygenase activity; glyceryl etherase activity; glyceryl-ether cleaving enzyme activity; O-alkylglycerol monooxygenase activity |
| Major function | Oxidative cleavage of the ether bond in 1-alkyl-sn-glycerol using O2 and a tetrahydropterin cofactor |
| Reaction | 1-alkyl-sn-glycerol + O2 + tetrahydrobiopterin/tetrahydropteridine = 1-hydroxyalkyl-sn-glycerol + H2O + dihydrobiopterin/dihydropteridine |
| Cofactor dependence | Tetrahydrobiopterin (or related tetrahydropterin) and metal ions |
| Subcellular context | Microsomal membranes |
| Tissue distribution | Widespread occurrence detected across rat tissues |
What Is GO:0050479?
In practical terms, GO:0050479 describes the catalysis of the reaction: 1-alkyl-sn-glycerol + O2 + (tetrahydrobiopterin/tetrahydropteridine) = 1-hydroxyalkyl-sn-glycerol + H2O + (dihydrobiopterin/dihydropteridine). The activity cleaves the O-alkyl ether bond of a glyceryl ether lipid and requires a reduced pterin cofactor, typically tetrahydrobiopterin, to donate electrons during the oxidation. It is a microsomal enzyme activity and is distinct from hydrolases or peroxidases that act on other lipid substrates.
Why Is glyceryl-ether monooxygenase activity Important in Cell Biology?
GO:0050479 is important because it defines a rate-limiting enzymatic step in ether lipid catabolism and because its cofactor requirement links lipid metabolism to pterin biochemistry. Ether lipids, including plasmalogens, are essential membrane components, and their remodeling depends on enzymes such as glyceryl-ether monooxygenase. The activity has been detected broadly in rat tissues, suggesting roles in multiple organ systems. Pharmacological inhibition of AGMO reduces adipogenesis in 3T3-L1 cells, indicating that this activity contributes to metabolic cell-fate decisions. In addition, disorders of biopterin metabolism can affect enzymes that depend on tetrahydrobiopterin, making this activity relevant to inherited metabolic disease.
• Defines a specific catalytic step in ether lipid metabolism that can be assayed biochemically.
• Requires tetrahydrobiopterin, connecting it to pterin metabolism and related disorders.
• Is widespread across rat tissues, supporting broad physiological roles.
• Contributes to adipogenesis, as AGMO inhibition reduces 3T3-L1 differentiation.
• Provides a target for studying ether lipid substrate specificity in aqueous buffers.
• Shares mechanistic features with aromatic amino acid hydroxylases, aiding comparative enzymology.
• Can be perturbed by CRISPR to test causal roles in lipid and metabolic phenotypes.
• Relevant to microsomal membrane biology and lipid remodeling.
• Offers a readout for cofactor-dependent oxidation in cell models.
• Supports drug discovery efforts targeting ether lipid metabolism.
Molecular Mechanism of glyceryl-ether monooxygenase activity
Substrate recognition and ether lipid binding
In simple terms: The enzyme must first grab the correct ether lipid substrate.
Glyceryl-ether monooxygenase activity acts on 1-alkyl-sn-glycerol substrates, and the nature of these glyceryl-ether lipid substrates in aqueous buffer has been characterized biochemically. The enzyme is a microsomal activity, meaning substrate access occurs at membrane surfaces where ether lipids are concentrated. Substrate specificity studies indicate that the alkyl chain and sn-glycerol configuration are important for recognition.
Oxygen activation and cofactor use
In simple terms: Oxygen and a pterin cofactor are used to break the ether bond.
The reaction consumes O2 and a tetrahydropterin, producing water and a dihydropterin. The dependence of an alkyl glycol-ether monooxygenase activity upon tetrahydropterins was demonstrated directly, establishing the cofactor requirement. This places the catalytic cycle in the family of pterin-dependent monooxygenases.
Metal ion dependence
In simple terms: Metal ions help the enzyme work, similar to some other hydroxylases.
Glyceryl ether monooxygenase resembles aromatic amino acid hydroxylases in metal ion and tetrahydrobiopterin dependence. This similarity suggests a catalytic mechanism involving a metal center that activates oxygen or stabilizes intermediates. The metal dependence is a key experimental variable when assaying GO:0050479 activity in vitro.
Product formation and ether bond cleavage
In simple terms: The ether bond is broken, giving a hydroxylated product.
The defined reaction yields 1-hydroxyalkyl-sn-glycerol, H2O and a dihydropterin. This oxidative cleavage converts an ether-linked lipid into a hydroxylated product, which can then enter further metabolic pathways. The reaction is distinct from hydrolytic cleavage because it requires O2 and a reduced pterin.
Tissue and cellular context of activity
In simple terms: This activity happens in many tissues and in microsomal membranes.
A novel assay detected widespread occurrence of glyceryl ether monooxygenase activity in rat tissues, indicating that the activity is not restricted to one organ. The enzyme is described as a microsomal enzyme of ether lipid metabolism. This subcellular localization shapes how substrates and cofactors reach the active site.
Key Genes Involved in GO:0050479 glyceryl-ether monooxygenase activity
The genes and proteins most directly associated with glyceryl-ether monooxygenase activity include the enzyme itself and its cofactor-related pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AGMO | Encodes alkylglycerol monooxygenase, the enzyme catalyzing GO:0050479 | Primary target for knockout, inhibition and mechanistic studies |
| GNPAT | Involved in ether lipid biosynthesis, providing substrates for ether lipid metabolism | Context for substrate supply to glyceryl-ether monooxygenase |
| GPD1 | Glycerol-3-phosphate metabolism linked to lipid synthesis | Metabolic context for glyceryl ether substrates |
| GPD2 | Mitochondrial glycerol-3-phosphate dehydrogenase, lipid redox context | Indirect metabolic context |
| PLA2G6 | Phospholipase involved in lipid remodeling | Related lipid metabolic pathway |
| FAR1 | Fatty acyl-CoA reductase involved in ether lipid synthesis | Upstream of ether lipid substrate pools |
| FAR2 | Fatty acyl-CoA reductase involved in ether lipid synthesis | Upstream of ether lipid substrate pools |
| PEX7 | Peroxisomal targeting, relevant to ether lipid synthesis | Context for ether lipid metabolism |
| GNPAT | Peroxisomal ether lipid synthesis enzyme | Substrate provision for ether lipids |
| DHFR | Dihydrofolate reductase, linked to tetrahydrobiopterin regeneration | Cofactor availability for pterin-dependent enzymes |
| GCH1 | GTP cyclohydrolase 1, rate-limiting in tetrahydrobiopterin synthesis | Cofactor supply for GO:0050479 |
| PTS | 6-pyruvoyltetrahydropterin synthase, tetrahydrobiopterin synthesis | Cofactor supply and biopterin disorders |
| SPR | Sepiapterin reductase, tetrahydrobiopterin synthesis | Cofactor supply and biopterin disorders |
| QDPR | Quinoid dihydropteridine reductase, regenerates tetrahydrobiopterin | Cofactor recycling for pterin-dependent oxidation |
| PAH | Phenylalanine hydroxylase, a pterin-dependent hydroxylase | Comparative mechanism with glyceryl-ether monooxygenase |
| TH | Tyrosine hydroxylase, a pterin-dependent hydroxylase | Comparative mechanism and cofactor dependence |
| TPH1 | Tryptophan hydroxylase 1, a pterin-dependent hydroxylase | Comparative mechanism and cofactor dependence |
How Is glyceryl-ether monooxygenase activity Regulated?
Glyceryl-ether monooxygenase activity is regulated at the level of substrate availability, cofactor supply and enzyme expression. The reaction requires a tetrahydropterin cofactor, so pathways controlling tetrahydrobiopterin synthesis and regeneration influence activity. Metal ion availability also modulates the enzyme, as it resembles aromatic amino acid hydroxylases in metal ion dependence. Pharmacological inhibition of AGMO reduces 3T3-L1 adipogenesis, indicating that the activity can be regulated by small molecules and that it participates in metabolic signaling. Tissue-specific detection of activity suggests that local expression or post-translational regulation contributes to its distribution.
glyceryl-ether monooxygenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AGMO | Adipogenesis and ether lipid metabolism | AGMO knockout and overexpression in 3T3-L1 cells |
| GCH1 | Disorders of biopterin metabolism | Point-mutation knock-in to model cofactor deficiency |
| QDPR | Biopterin recycling defects | Knockout or point-mutation models with activity assays |
| PAH | Pterin-dependent hydroxylase deficiency | Comparative point-mutation models for mechanism |
| AGMO | Ether lipid substrate handling | Knock-in of tagged AGMO for localization and activity |
Disorders of biopterin metabolism
Disorders of biopterin metabolism affect enzymes that depend on tetrahydrobiopterin, and glyceryl-ether monooxygenase activity is tetrahydrobiopterin-dependent. Therefore, perturbations in biopterin synthesis or regeneration could alter this activity and contribute to metabolic phenotypes. Studying GO:0050479 in patient-derived or CRISPR models can help clarify whether ether lipid metabolism is affected in these disorders.
Metabolic and adipogenesis-related biology
AGMO inhibition reduces 3T3-L1 adipogenesis, linking glyceryl-ether monooxygenase activity to adipocyte differentiation. This suggests that the activity may influence lipid storage and metabolic cell fate. Experimental models that modulate AGMO can test whether the catalytic activity is required for adipogenesis.
Ether lipid metabolism and membrane biology
Glyceryl-ether monooxygenase is a microsomal enzyme of ether lipid metabolism, and defects in ether lipid pathways can affect membrane composition. The activity cleaves ether bonds, so its loss may alter the balance of ether-linked and hydroxylated lipids. Researchers can use biochemical assays to measure whether disease-associated variants change catalytic efficiency.
From glyceryl-ether monooxygenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is AGMO required for adipogenesis? | AGMO knockout in 3T3-L1 cells |
| Does a disease variant alter catalytic activity? | Point-mutation knock-in of AGMO |
| Where is the enzyme localized in cells? | Tagged knock-in of AGMO |
| Does overexpression increase ether lipid cleavage? | AGMO overexpression in cultured cells |
| Does cofactor deficiency reduce activity? | Knockout of GCH1 or QDPR with activity assays |
| Can small molecules inhibit the activity? | AGMO inhibitor treatment in cell models |
How to Study the glyceryl-ether monooxygenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic activity assay | Catalytic conversion of 1-alkyl-sn-glycerol | Detecting GO:0050479 in tissues or cell lysates |
| CRISPR knockout | Loss of enzyme function | Testing requirement for adipogenesis |
| Point-mutation knock-in | Effect of specific residues on catalysis | Mechanistic dissection of active site |
| Tagged knock-in | Protein localization and interactions | Microsomal localization studies |
| Lipidomics | Changes in ether lipid species | Linking activity to lipid pools |
| Cofactor supplementation assay | Dependence on tetrahydrobiopterin | Testing cofactor requirement |
| Inhibitor treatment | Pharmacological inhibition of activity | Testing metabolic consequences |
| Comparative hydroxylase assays | Mechanistic similarity to PAH/TH | Enzyme family comparisons |
Enzymatic activity assays
Direct measurement of glyceryl-ether monooxygenase activity can be performed using assays that monitor substrate consumption or product formation in the presence of tetrahydropterin and O2. A novel assay enabled detection of widespread activity in rat tissues, demonstrating the utility of sensitive biochemical methods. Substrate specificity can be tested in aqueous buffer to define which glyceryl-ether lipids are preferred.
Genetic perturbation with CRISPR
CRISPR knockout of AGMO can eliminate the activity and test its cellular functions. Point mutations can be introduced to dissect catalytic residues or cofactor-binding sites. Knock-in of tags allows localization and interaction studies in the native genomic context.
Lipidomics and metabolic profiling
Because the activity changes ether lipid species, lipidomic profiling can quantify substrate and product levels. Combining lipidomics with genetic perturbation helps link GO:0050479 to specific lipid pools. Metabolic profiling in adipogenesis models can reveal downstream consequences of altered activity.
Cofactor and metal analysis
Since the enzyme depends on tetrahydrobiopterin and metal ions, assays should control cofactor and metal availability. Comparative studies with aromatic amino acid hydroxylases can guide mechanistic interpretation. Biopterin metabolism disorders provide a context for testing cofactor effects.
How CRISPR Can Be Used to Study GO:0050479 glyceryl-ether monooxygenase activity
Knockout
CRISPR knockout of AGMO eliminates glyceryl-ether monooxygenase activity, providing a clean background to test its role in ether lipid metabolism and adipogenesis. Knockout models can be used to measure substrate accumulation and product loss.
Point Mutation
Point mutations can be introduced into AGMO to test catalytic residues and cofactor-binding motifs suggested by its similarity to aromatic amino acid hydroxylases. Such models help distinguish loss-of-function from altered-specificity variants.
Knock-in
Knock-in of epitope tags or reporters at the endogenous AGMO locus enables localization and activity studies in the native chromatin context. This is useful for confirming microsomal localization and for interaction proteomics.
Overexpression
Overexpression of AGMO can amplify the activity for biochemical assays and for testing whether increased ether lipid cleavage alters cellular lipid composition. Overexpression models are also useful for inhibitor testing.
How EDITGENE Supports glyceryl-ether monooxygenase activity Research
Researchers studying glyceryl-ether monooxygenase activity-related genes often need to determine whether a candidate gene is causally involved in ether lipid metabolism, adipogenesis or cofactor-dependent oxidation. EDITGENE provides the CRISPR tools and cell models needed to move from correlation to causation.
Contact EDITGENE today to design your custom CRISPR model for glyceryl-ether monooxygenase activity research.
Frequently Asked Questions About glyceryl-ether monooxygenase activity
What is glyceryl-ether monooxygenase activity?
It is the enzyme activity defined by GO:0050479 that cleaves the ether bond of 1-alkyl-sn-glycerol using O2 and a tetrahydropterin cofactor.
What reaction does GO:0050479 catalyze?
The reaction is 1-alkyl-sn-glycerol + O2 + tetrahydrobiopterin/tetrahydropteridine = 1-hydroxyalkyl-sn-glycerol + H2O + dihydrobiopterin/dihydropteridine.
What genes are involved in glyceryl-ether monooxygenase activity?
AGMO encodes the enzyme, while GCH1, QDPR and other genes support tetrahydrobiopterin cofactor supply.
Which cofactor does glyceryl-ether monooxygenase require?
It requires a tetrahydropterin, typically tetrahydrobiopterin, and shows metal ion dependence.
Where is glyceryl-ether monooxygenase activity found in the body?
It is a microsomal activity and has been detected widely across rat tissues.
Is glyceryl-ether monooxygenase the same as alkylglycerol monooxygenase?
Yes, alkylglycerol monooxygenase activity is a synonym for GO:0050479.
How can I study glyceryl-ether monooxygenase activity in cells?
Use enzymatic assays, CRISPR knockout of AGMO, lipidomics and cofactor supplementation experiments.
What diseases are linked to glyceryl-ether monooxygenase activity?
Disorders of biopterin metabolism and metabolic phenotypes such as adipogenesis are linked to this activity.
Does AGMO inhibition affect adipogenesis?
Yes, an AGMO inhibitor reduces 3T3-L1 adipogenesis.
What CRISPR models are available for GO:0050479 research?
Knockout, point-mutation, knock-in, tagged knock-in and overexpression models can be generated for AGMO and related genes.
Conclusion
Glyceryl-ether monooxygenase activity (GO:0050479) is a well-defined, tetrahydrobiopterin-dependent molecular function that cleaves ether lipids in microsomal membranes. Its broad tissue distribution and links to adipogenesis and biopterin metabolism make it a compelling target for metabolic and lipid research. CRISPR-based models provide the causal tools needed to dissect its roles in health and disease.
References
- 1. Watschinger K et al.. 2013. Alkylglycerol monooxygenase.. IUBMB Life 65(4):366-72 PMID: 23441072
- 2. Taguchi H et al.. 1998. Glyceryl-ether monooxygenase [EC 1.14.16.5]. A microsomal enzyme of ether lipid metabolism.. Med Res Rev 18(1):43-89 PMID: 9436181
- 3. Watschinger K et al.. 2009. Glyceryl ether monooxygenase resembles aromatic amino acid hydroxylases in metal ion and tetrahydrobiopterin dependence.. Biol Chem 390(1):3-10 PMID: 19007315
- 4. Werner ER et al.. 2007. Widespread occurrence of glyceryl ether monooxygenase activity in rat tissues detected by a novel assay.. J Lipid Res 48(6):1422-7 PMID: 17303893
- 5. Longo N. 2009. Disorders of biopterin metabolism.. J Inherit Metab Dis 32(3):333-42 PMID: 19234759
- 6. Fischer C et al.. 2021. AGMO Inhibitor Reduces 3T3-L1 Adipogenesis.. Cells 10(5) PMID: 34062826
- 7. Taguchi H et al.. 1994. Glyceryl-ether monooxygenase (EC 1.14.16.5): nature of the glyceryl-ether lipid substrates in aqueous buffer.. Biol Chem Hoppe Seyler 375(5):329-34 PMID: 8074806
- 8. Kaufman S et al.. 1990. Dependence of an alkyl glycol-ether monooxygenase activity upon tetrahydropterins.. Biochim Biophys Acta 1040(1):19-27 PMID: 2378898
